heredERA Breast Cancer: a phase III, randomized, open-label study evaluating the efficacy and safety of giredestrant plus the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection in patients with previously untreated HER2-positive, estrogen receptor-positive locally advanced or metastatic breast cancer

Peer Review reports

Original Submission
4 Aug 2023	Submitted	Original manuscript
22 Sep 2023	Reviewed	Reviewer Report
12 Dec 2023	Reviewed	Reviewer Report
2 Jan 2024	Reviewed	Reviewer Report
26 Jan 2024	Author responded	Author comments - Joyce O’Shaughnessy
2 Feb 2024	Author responded	Author comments - Joyce O’Shaughnessy
Resubmission - Version 2
26 Jan 2024	Submitted	Manuscript version 2
5 Feb 2024	Author responded	Author comments - Joyce O’Shaughnessy
Resubmission - Version 3
5 Feb 2024	Submitted	Manuscript version 3
11 Feb 2024	Reviewed	Reviewer Report
21 Feb 2024	Reviewed	Reviewer Report
25 Mar 2024	Author responded	Author comments - Joyce O’Shaughnessy
Resubmission - Version 4
25 Mar 2024	Submitted	Manuscript version 4
Publishing
25 Mar 2024	Editorially accepted
24 May 2024	Article published	10.1186/s12885-024-12179-9

Back to article page